Anisindione

Breastfeeding
  • TRADE NAME: Miradon (Schering)
  • INDICATIONS: Adjunct in treatment of coronary occlusion, atrial fibrillation
  • CLASS: Anticoagulant, Indanedione
  • HALF-LIFE: 3–5 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amiodarone, Anabolic steroids, Antithyroid agents, Barbiturates, Bivalirudin, Cimetidine, Clofibrate, Clopidogrel, Cyclosporine, Delavirdine, Dextrothyroxine, Disulfiram, Fluconazole, Glutethimide, Imatinib, Itraconazole, Ketoconazole, Metronidazole, Miconazole, Nandrolone, Penicillins, Phenylbutazones, Piperacillin, Quinidine, Quinine, Rifabutin, Rifampin, Rifapentine, Rofecoxib, Salicylates, Sulfinpyrazone, Sulfonamides, Testosterone, Thyroid, Zileuton

Our database has 4 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

MUCOSAL.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.


Page last updated 09/03/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top